Continuation of Group B Streptococcus Epidemiology Study (Phase II)Kaiser Permanente Northern California has recently collaborated with Pfizer in identifying invasive and noninvasive group B streptococcus (GBS) disease burden in adults during a seven-year time period spanning 2007 to 2014. In Phase 1 of this research collaboration, comorbid medical conditions in subjects with GBS disease were identified. In Phase 2 of this research collaboration, the burden of invasive and/or noninvasive GBS disease among subjects with the most commonly identified medical conditions identified in Phase 1 will be evaluated. These data will inform potential future study populations for the evaluation of a GBS vaccine in adults. The objective is to identify populations at highest risk for GBS disease (invasive and noninvasive) based on the pre-specified medical conditions and age groups from the Phase 1 analyses. Prediction models for patient risks of GBS will be developed, and with the models, each risk factor and combination of risk factors will be evaluated.
Investigator: Klein, Nicola
Funder: Pfizer Inc.